|

Akt/ERK Inhibitor ONC201 Clinical Trials

2 actively recruiting trials across 2 locations

Also known as: ONC-201, ONC201, TIC10

Pipeline

Phase 2: 1Phase 1/2: 1

Top Sponsors

  • M.D. Anderson Cancer Center1
  • Ira Winer1

Indications

  • Cancer2
  • Malignant Ovarian Epithelial Tumor1
  • Refractory Primary Peritoneal Carcinoma1
  • Refractory Fallopian Tube Carcinoma1
  • Recurrent Ovarian Carcinoma1

Detroit, Michigan1 trial

ONC201 Plus Weekly Paclitaxel in Patients With Platinum Refractory or Resistant Ovarian Cancer

Barbara Ann Karmanos Cancer Institute

Phase 2

Houston, Texas1 trial

ONC201 in Treating Patients With Relapsed or Refractory Acute Leukemia or High-Risk Myelodysplastic Syndrome

M D Anderson Cancer Center

Phase 1/2

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.